Sep 3, 2026, 04:12 UTC
Hutchison China MediTech and GlaxoSmithKline reached a licensing agreement for a KRAS-EGFR antibody-drug conjugate cancer drug.
Sep 1, 2026, 06:04 UTC
GlaxoSmithKline announced positive Phase 2 trial data and will advance development of a candidate vaccine.
Aug 31, 2026, 11:30 UTC
Aurobindo Pharma's subsidiary Lannett Company LLC launched a generic version of Advair Diskus in the US market.
Source:Aug 24, 2026, 12:30 UTC
The FTSE 100 rose 13 points to 10,830 by midday on 24 August 2026, led by miners and travel stocks, while the FTSE 250 slipped 0.1% to 24,703.
Source:Aug 24, 2026, 07:06 UTC
GSK announced that its experimental chronic hepatitis B drug received its first global approval in Japan, and its cancer therapy was granted priority U.S. regulatory review as a possible rectal cancer treatment.
Aug 21, 2026, 09:30 UTC
GSK shares dropped 1.72% to 1,887.50p on August 21, 2026.
Source:Aug 19, 2026, 21:46 UTC
GSK PLC shares rose 3.4% to $52.88 on August 19, 2026.
Source:Aug 18, 2026, 14:23 UTC
GSK announced that Canada's drug agency issued a positive reimbursement recommendation for NUCALA (mepolizumab) for the treatment of chronic obstructive pulmonary disease in adults.
Source:Aug 18, 2026, 02:38 UTC
Chugai Pharmaceutical and GlaxoSmithKline signed an exclusive license agreement on August 18, 2026, granting GSK global rights to develop, manufacture, and commercialize the dengue antibody drug AID351, with Chugai eligible for royalties and a share of sublicensing revenue.
Source:Aug 17, 2026, 22:00 UTC
The UK government announced on August 12 that it is investing 22 million pounds, including 20 million pounds for a new Pre-clinical Translational Models Hub in Cambridge, to grow miniature human organs from NHS patients' cells for drug testing.
Source:Aug 14, 2026, 11:45 UTC
The FTSE 100 index traded marginally lower on Friday, with mining stocks declining sharply due to weak metal prices while energy stocks gained on higher oil prices.
Source:Jul 30, 2026, 09:15 UTC
GSK and Relation Therapeutics entered into a research collaboration worth up to $110 million to generate human cellular datasets and train AI models for identifying potential new drug targets.
Jul 28, 2026, 18:30 UTC
GSK completes the acquisition of US-based cancer specialist Nuvalent for nearly £8 billion.
Source:Jul 28, 2026, 14:11 UTC
GSK plans to start at least 20 Phase 3 trials in 2026, up from the previously disclosed 10.
Source:Jul 28, 2026, 11:09 UTC
GSK reported second-quarter profit that beat expectations on July 28, 2026.
Jul 28, 2026, 10:17 UTC
GSK and Hansoh Pharmaceutical announced that their experimental drug Ris-Rez met the primary endpoint of progression-free survival in a late-stage trial for bone cancer.
Source:Jul 22, 2026, 17:58 UTC
The US FDA approved GSK's Jideytro (zidesamtinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have received a prior ROS1 kinase inhibitor.
Jul 17, 2026, 00:00 UTC
GSK discontinues development of camlipixant, an experimental chronic cough medicine, after mixed Phase 3 data.
Jul 14, 2026, 13:31 UTC
GSK announces positive interim phase II data for its drug Jemperli in rectal cancer, meeting the primary endpoint and supporting potential regulatory filings.
Source:Jun 24, 2026, 19:36 UTC
Nuvalent, Inc. agreed to be acquired by GSK plc for $124.00 per share in cash.
Jun 17, 2026, 16:36 UTC
The US FDA approved Utebzi (tebipenem pivoxil), an oral antibiotic developed by GSK and Spero Therapeutics, for adults with complicated urinary tract infections in the US.
Jun 12, 2026, 14:56 UTC
GSK's momelotinib received orphan drug designation from the FDA and EMA for VEXAS syndrome.
Source:Jun 8, 2026, 10:16 UTC
Engitix entered a strategic collaboration with GSK to advance first-in-class targets for liver fibrosis regression using Engitix's human ECM platform.
Source: